What is Plexium?
Plexium is at the forefront of precision medicine, focusing on the identification and modulation of E3 ligases, key regulators of protein degradation, to develop novel therapeutics. Their proprietary DELPhe platform represents a significant technological advancement, enabling rapid and efficient screening of vast chemical libraries against cellular targets. This capability is crucial for discovering small molecules that can precisely control protein levels, offering a promising avenue for treating complex diseases such as cancer and neurodegenerative disorders. The company's approach aims to unlock new therapeutic modalities by targeting previously undruggable proteins.
How much funding has Plexium raised?
Plexium has raised a total of $225.1M across 4 funding rounds:
Series A
$28M
Other Financing Round
$35M
Other Financing Round
$102M
Private Equity
$60.1M
Series A (2019): $28M with participation from M Ventures, Neotribe Ventures, CRV, DCVC Bio, and The Column Group
Other Financing Round (2021): $35M led by DCVC Bio, PIVOTAL BIOVENTURE PARTNERS LLC, The Column Group, and Lux Capital
Other Financing Round (2022): $102M supported by Pappas Capital, L.P., RA Capital Management, Surveyor Capital, TCG X, Softbank Vision Fund 2, and BVF Partners
Private Equity (2025): $60.1M, investors not publicly disclosed
Key Investors in Plexium
Pappas Capital
Pappas Capital is a global investment firm with over 31 years of experience, dedicated to advancing life science discoveries and investing in companies developing next-generation products and technologies. They have a broad portfolio across the United States, Canada, and Asia, focusing on a wide range of human diseases and generating substantial returns.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics. They aim to partner with innovators to bring ideas from the lab to the clinic.
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in innovative technologies and products with the potential to significantly impact Merck's core business areas. They actively support their portfolio companies to translate innovation towards commercial success.
What's next for Plexium?
With the recent influx of major strategic investment, Plexium is poised to accelerate its drug discovery and development pipeline. The substantial capital infusion, coupled with the company's advanced screening technology, suggests a strategic focus on advancing lead candidates into clinical trials and expanding its therapeutic portfolio. This enterprise-level funding indicates Plexium is moving towards scaling its operations, potentially building out its research and development infrastructure, and forging strategic partnerships to bring its innovative treatments to patients. The company's trajectory points towards significant growth and a potential leadership position in the targeted protein degradation space.
See full Plexium company page
